Additionally, platelet reactivity has a pivotal role during AMI, and patients with DM present with several platelets abnormalities which lead to poor responsiveness to antiplatelet therapy including acetylsalicylic acid (ASA) and P2Y12 inhibitors (P2Y12-i) [5,6,7]. Here, P2RY12 is linked to diabetes mellitus.